Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neurotransmitter functions in depression.

Y D Lapierre

    Progress in Neuro-Psychopharmacology & Biological Psychiatry
    |January 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    This study explores neurotransmitter roles in depression, suggesting specific metabolites like MHPG could help classify depression subtypes. Understanding these biochemical pathways offers new avenues for targeted antidepressant treatments.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Fluphenazine, trifluoperazine and perphenazine in Vacutainers.

    Canadian Medical Association journal·2010
    Same author

    What are the issues surrounding long-term benzodiazepine treatment for generalized anxiety disorder.

    Journal of psychiatry & neuroscience : JPN·2001
    Same author

    Association of polymorphism of serotonin 2A receptor gene with suicidal ideation in major depressive disorder.

    American journal of medical genetics·2000
    Same author

    Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia.

    Canadian journal of psychiatry. Revue canadienne de psychiatrie·1999
    Same author

    Obsessive-compulsive spectrum disorders: effective treatment with paroxetine.

    Canadian journal of psychiatry. Revue canadienne de psychiatrie·1999
    Same author

    Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression.

    Psychiatry research·1999
    Same journal

    Single Ayahuasca administration attenuates alcohol relapse and associated behavioral, neurochemical, and oxidative alterations in rats.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Altered dorsal striatal subregional connectivity associated with distinct executive function deficits in first-episode, drug-naïve major depressive disorder: Evidence from functional connectivity and granger causality analysis.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Chronic pain and stress: unravelling the common neuroinflammatory, immune and endocrine mechanisms for novel therapeutic approaches.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Predicting anhedonia and negative cognitive processing changes after 8-week SSRIs treatment in depression from individual differential structural covariance network.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Mapping intrinsic neural timescale alterations in major depressive disorder.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    Same journal

    Probiotics in reducing negative symptoms of schizophrenia: A systematic review and meta-analysis.

    Progress in neuro-psychopharmacology & biological psychiatry·2026
    See all related articles

    Area of Science:

    • Neuroscience
    • Psychiatry
    • Biochemistry

    Background:

    • Depression subtypes may have distinct biochemical underpinnings.
    • Neurotransmitter systems are implicated in mood regulation.
    • Current understanding of antidepressant mechanisms requires further elucidation.

    Purpose of the Study:

    • To investigate the potential of specific neurochemicals in classifying depression subtypes.
    • To explore the relationship between neurotransmitter activity and mood/behavior.
    • To elucidate the mechanisms of action for antidepressant drugs and electroconvulsive therapy (ECT).

    Main Methods:

    • Analysis of cerebrospinal fluid (CSF) metabolites, including 5-hydroxyindoleacetic acid (5-HIAA).
    • Measurement of homovanillic acid (HVA) and 3-methoxy-4-hydroxyphenylglycol (MHPG) levels.

    Related Experiment Videos

  • Review of existing literature on acetylcholine, GABA, and adrenergic receptor function in relation to mood disorders.

    • Main Results:

    • MHPG levels may aid in identifying and treating distinct depression subgroups.
    • HVA shows a stronger correlation with activity levels than with mood states.
    • CSF-5-HIAA could be valuable for categorizing certain types of depression.
    • Acetylcholine influences mood indirectly, likely via other neurotransmitters.
    • GABA's role in depression remains insufficiently studied.
    • Desensitization of presynaptic adrenergic autoreceptors is a potential mechanism for antidepressant drug efficacy.
    • Reduced post-synaptic adrenergic activity is a common effect of antidepressants and ECT.

    Conclusions:

    • Neurochemical profiling offers a promising approach for stratifying depression.
    • Further research into GABAergic systems is warranted.
    • Adrenergic system modulation is a key target for antidepressant therapies and ECT.